… pricing of its underwritten initial public offering of 11,000,000 … its common stock at the initial public offering price, less underwriting discounts … AMERICA INDUSTRY KEYWORD: HEALTH GENETICS RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY SOURCE: Edgewise …

… anniversary of Consonance-HFW’s IPO. Lead investors in the PIPE … Consonance-HFW related to its initial public offering and in its Annual Report … : SCIENCE CARDIOLOGY OTHER SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL GENERAL HEALTH HEALTH SOURCE: Consonance …

… celebration of its recently completed initial public offering (IPO). Snehal Patel, CEO of … breast cancer recurrences. With the IPO and follow-on offering, … : SCIENCE OTHER SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY GENERAL HEALTH HEALTH SOURCE …

… Successful Completion of Initial Public Offering (IPO). Spruce closed its IPO in October … ,158 Adjustments:       Net IPO proceeds after deducting underwriting discounts … SCIENCE OTHER SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL GENERAL HEALTH HEALTH OTHER …

… financing since its March 2018 initial public offering, providing new and existing stockholders … AMERICA INDUSTRY KEYWORD: ONCOLOGY HEALTH RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY SOURCE: Arcus Biosciences …

… San Diego. Codex DNA, which IPO’d in June at $16 … synthesis, for the global academic research, pharmaceutical and biotechnology industries. The company …

… or commencement contingent on our initial public offering in 2018. The increase for … KEYWORD: SCIENCE OTHER SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH GENETICS CLINICAL TRIALS SOURCE …

… well as a pre-IPO funding round to advance … where he led a successful IPO and listing) and Sosei … has advised multiple companies on IPOs and M&As. … KEYWORD: HEALTH INFECTIOUS DISEASES RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY Copyright Business Wire …

… , concurrently with the proposed initial public offering of the Purchaser and listing … in the event that the initial public offering of the Purchaser is not … core business pillars: clinical research, pharmaceutical promotion and retail commercialization of …

… following the Purchaser' initial public offering, 15,000,000 common shares … capital of the Purchaser post-initial public offering. The intention is for … core business pillars: clinical research, pharmaceutical promotion and retail commercialization of …